Blocking ephrinB2 with highly specific antibodies inhibits angiogenesis, lymphangiogenesis, and tumor growth

Blood

Volumn 119, Issue 19, 2012, Pages 4565-4576

  Abéngozar, María Angeles ^a   De Frutos, Sergio ^b   Ferreiro, Sergio ^a   Soriano, Joaquím ^a   Perez Martinez, Manuel ^a   Olmeda, David ^a   Marenchino, Marco ^a   Cañamero, Marta ^a   Ortega, Sagrario ^a   Megias, Diego ^a   Rodriguez, Antonio ^b   Martínez Torrecuadrada, Jorge L ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; EPHRIN; EPHRIN B2; EPHRIN RECEPTOR B4; LIGAND; MATRIGEL; SINGLE CHAIN FRAGMEN VARIABLE ANTIBODY 2B1; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY B11; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING COMPETITION; CELL INTERACTION; CELL MIGRATION; CELL MOTILITY; CELL STRAIN HEK293; CONTROLLED STUDY; CYTOSKELETON; DRUG MECHANISM; DRUG RECEPTOR BINDING; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPH VESSEL; LYMPHANGIOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL;

EID: 84861083859     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-09-380006     Document Type: Article

References (41)

1. Risau W. Mechanisms of angiogenesis. Nature. 1997;386(6626):671-674. (Pubitemid 27193480)
2. Oliver G. Lymphatic vasculature development. Nat Rev Immunol. 2004;4(1):35-45. (Pubitemid 38084130)
3. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407(6801):249-257.
4. Carmeliet P. Angiogenesis in life, disease and medicine. Nature. 2005;438(7070):932-936. (Pubitemid 43093958)
5. Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature. 2005;438(7070):946-953. (Pubitemid 43093960)
6. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005;333(2):328-335. (Pubitemid 40848295)
7. Sebolt-Leopold JS, English JM. Mechanisms of drug inhibition of signalling molecules. Nature. 2006;441(7092):457-462. (Pubitemid 44050141)
8. Dancey JE, Chen HX. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat Rev Drug Discov. 2006;5(8):649-659. (Pubitemid 44151603)
9. Jubb AM, Harris AL. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol. 2010;11(12):1172-1183.
10. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15(3):220-231.
11. Adams RH, Klein R. Eph receptors and ephrin ligands. essential mediators of vascular development. Trends Cardiovasc Med. 2000;10(5):183-188. (Pubitemid 32229885)
12. Makinen T, Adams RH, Bailey J, et al. PDZ interaction site in ephrinB2 is required for the remodeling of lymphatic vasculature. Genes Dev. 2005; 19(3):397-410. (Pubitemid 40189302)
13. Kullander K, Klein R. Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol. 2002;3(7):475-486. (Pubitemid 34733429)
14. Pasquale EB. Eph-ephrin bidirectional signaling in physiology and disease. Cell. 2008;133(1):38-52. (Pubitemid 351442996)
15. Himanen JP, Chumley MJ, Lackmann M, et al. Repelling class discrimination: ephrin-A5 binds to and activates EphB2 receptor signaling. Nat Neurosci. 2004;7(5):501-509. (Pubitemid 38544589)
16. Kalo MS, Yu HH, Pasquale EB. In vivo tyrosine phosphorylation sites of activated ephrin-B1 and ephB2 from neural tissue. J Biol Chem. 2001; 276(42):38940-38948.
17. Lin D, Gish GD, Songyang Z, Pawson T. The carboxyl terminus of B class ephrins constitutes a PDZ domain binding motif. J Biol Chem. 1999; 274(6):3726-3733. (Pubitemid 29077220)
18. Essmann CL, Martinez E, Geiger JC, et al. Serine phosphorylation of ephrinB2 regulates trafficking of synaptic AMPA receptors. Nat Neurosci. 2008; 11(9):1035-1043.
19. Sawamiphak S, Seidel S, Essmann CL, et al. Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature. 2010;465(7297):487- 491.
20. Wang Y, Nakayama M, Pitulescu ME, et al. Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature. 2010; 465(7297):483-486.
21. Wang HU, Chen ZF, Anderson DJ. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell. 1998;93(5):741-753. (Pubitemid 28257581)
22. Gerety SS, Wang HU, Chen ZF, Anderson DJ. Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. Mol Cell. 1999;4(3):403-414. (Pubitemid 29499793)
23. Adams RH, Wilkinson GA, Weiss C, et al. Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/ venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev. 1999;13(3): 295-306. (Pubitemid 29095801)
24. Yamanda S, Ebihara S, Asada M, et al. Role of ephrinB2 in nonproductive angiogenesis induced by Delta-like 4 blockade. Blood. 2009;113(15): 3631-3639.
25. Zheng W, Tammela T, Yamamoto M, et al. Notch restricts lymphatic vessel sprouting induced by vascular endothelial growth factor. Blood. 2011; 118(4):1154-1162.
26. Bochenek ML, Dickinson S, Astin JW, Adams RH, Nobes CD. Ephrin-B2 regulates endothelial cell morphology and motility independently of Ephreceptor binding. J Cell Sci. 2010;123(Pt 8):1235-1246.
27. Martiny-Baron G, Korff T, Schaffner F, et al. Inhibition of tumor growth and angiogenesis by soluble EphB4. Neoplasia. 2004;6(3):248-257. (Pubitemid 38657081)
28. Kertesz N, Krasnoperov V, Reddy R, et al. The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth. Blood. 2006;107(6):2330-2338. (Pubitemid 43345552)
29. Martinez-Torrecuadrada J, Cifuentes G, Lopez-Serra P, Saenz P, Martinez A, Casal JI. Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation. Clin Cancer Res. 2005;11(17):6280-6290. (Pubitemid 41262959)
30. Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol. 2007;8(6):464-478. (Pubitemid 46823443)
31. Cristofaro B, Emanueli C. Possible novel targets for therapeutic angiogenesis. Curr Opin Pharmacol. 2009;9(2):102-108.
32. Krasnoperov V, Kumar SR, Ley E, et al. Novel EphB4 monoclonal antibodies modulate angiogenesis and inhibit tumor growth. Am J Pathol. 2010;176(4):2029-2038.
33. Koolpe M, Burgess R, Dail M, Pasquale EB. EphB receptor-binding peptides identified by phage display enable design of an antagonist with ephrin-like affinity. J Biol Chem. 2005; 280(17):17301-17311. (Pubitemid 41389199)
34. Scehnet JS, Ley EJ, Krasnoperov V, et al. The role of Ephs, Ephrins, and growth factors in Kaposi sarcoma and implications of EphrinB2 blockade. Blood. 2009;113(1):254-263.
35. Chrencik JE, Brooun A, Kraus ML, et al. Structural and biophysical characterization of the EphB4-ephrinB2 protein-protein interaction and receptor specificity. J Biol Chem. 2006;281(38): 28185-28192. (Pubitemid 44414532)
36. Steinle JJ, Meininger CJ, Chowdhury U, Wu G, Granger HJ. Role of ephrin B2 in human retinal endothelial cell proliferation and migration. Cell Signal. 2003;15(11):1011-1017. (Pubitemid 37130159)
37. Toth J, Cutforth T, Gelinas AD, Bethoney KA, Bard J, Harrison CJ. Crystal structure of an ephrin ectodomain. Dev Cell. 2001;1(1):83-92. (Pubitemid 33586071)
38. Foo SS, Turner CJ, Adams S, et al. Ephrin-B2 controls cell motility and adhesion during bloodvessel-wall assembly. Cell. 2006;124(1):161-173. (Pubitemid 43069317)
39. Cowan CA, Henkemeyer M. The SH2/SH3 adaptor Grb4 transduces B-ephrin reverse signals. Nature. 2001;413(6852):174-179. (Pubitemid 32867879)
40. Keezer SM, Ivie SE, Krutzsch HC, Tandle A, Libutti SK, Roberts DD. Angiogenesis inhibitors target the endothelial cell cytoskeleton through altered regulation of heat shock protein 27 and cofilin. Cancer Res. 2003;63(19):6405-6412. (Pubitemid 37255190)
41. Cassella M, Skobe M. Lymphatic vessel activation in cancer. Ann N Y Acad Sci. 2002;979:120-130. (Pubitemid 36121144)